The generic version of Vemlidy could potentially become available after 15 February, 2033. This release date is speculated based on the expiration date of its last patent, US9296769*PED. The expired patent, US7803788, is not a hindrance to the release of Vemlidy generics.
Vemlidy is primarily used for the treatment of chronic hepatitis B in adult patients. The effectiveness of this drug comes from its active ingredient, tenofovir alafenamide fumarate, which is an antiviral medication.
Vemlidy is protected by 7 patents, with the latest one (US9296769*PED entitled 'Tenofovir alafenamide hemifumarate') expiring on 15 February, 2033. One of the patents (US7803788) has already expired. For more insights into when a Vemlidy generic could become available, refer to the patent details provided. Below are the details of the patents: